Business

Biotech, pharma, and money in science

Alex Gorsky
The Pharmalot View

From zero to hero: J&J CEO praises Trump one year after chastising him

By Ed Silverman

IF Patties
Business

The maker of the Impossible Burger tested its secret sauce in rats. Then PETA went on the attack

By Rebecca Robbins and Damian Garde

Vertex
Business

Vertex gets approval to treat toddlers with cystic fibrosis drug

By Jonathan Saltzman — Boston Globe

Lessons Learned
Lessons Learned

Lessons Learned: This is how you leave the bench for clinical consulting

By Megha Satyanarayana

Biotech

Musician-scientist Manny Simons and Akouos seek way to treat a gene-based hearing loss

By Jonathan Saltzman — Boston Globe

Dr. Atul Gawande
Business

Gawande says health venture is not seeking profits. But whose bottom line will it benefit?

By Casey Ross

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

Overprescribing Painkillers
Business

How rival opioid makers sought to cash in on alarm over OxyContin’s dangers

By Fred Schulte — Kaiser Health News

Lessons Learned
Lessons Learned

Lessons Learned: This is how you take a public health degree to a startup and back to academia

By Megha Satyanarayana

Paula Soteropoulos, CEO of Akcea Therapeutics.
Biotech

Two Akcea drugs are about to hit the market — but are they already too late?

By Kate Sheridan

Exclusive

In shift, IBM is adding regional treatment advice and real patient data to cancer product

By Ike Swetlitz and Casey Ross

A dosage of Spinraza.
Biotech

For UMass Medical School, Spinraza sales add millions to the budget

By Kate Sheridan

Hepatitis Drugs
Adam's Take

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

By Adam Feuerstein

A photo of Venture capitalist Lisa Suennen.
Business

VCs are pouring money into digital health. Are they making smart bets?

By Rebecca Robbins and Adam Feuerstein

A photo of Lenny Parker and TJ Parker.
Business

At PillPack, a lot of credit goes to the father of invention

By Scott Kirsner — Boston Globe

Lessons Learned
Lessons Learned

Lessons Learned: This is how you become a venture capitalist in biotech

By Megha Satyanarayana

Toby Cosgrove Google
Business

Powerful people in health care are finding a new landing pad: Google

By Rebecca Robbins

Adam's Take

Gilead’s golden era ends with the executive departures of ‘The Johns’

By Adam Feuerstein

Biotech

Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment

By Damian Garde

Phone Therapeutics
Business

Prescription apps are gaining ground — and drug makers’ backing — as digital therapeutics

By Kate Sheridan

Sick Watson
Exclusive

IBM’s Watson supercomputer recommended ‘unsafe and incorrect’ cancer treatments, internal documents show

By Casey Ross and Ike Swetlitz

Business

Biogen rare-disease drug bounces back with strong sales in the second quarter

By Adam Feuerstein

Adam's Take

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

By Adam Feuerstein

DEA Prescription Drug
Pharmalot

Pricing pledges from drug makers include plenty of fine print

By Ed Silverman

Craig Venter
Biotech

In lawsuit, Human Longevity alleges that Craig Venter stole trade secrets

By Rebecca Robbins

D.C. Insight IMAGE
Business

PhRMA breaks its half-year record for federal lobbying spending

By Rebecca Robbins

Limbix Anxiety Tech Bar Scene
Business

The opportunity ‘is huge’: Why tech developers are trying to tackle mental health

By Rebecca Robbins

STAT Live

Archived: A chat to discuss Amazon’s pivot into health care

By Casey Ross and Ike Swetlitz

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy